Market Overview

Dicerna to Participate in Upcoming Investor Conferences


Pharmaceuticals, Inc.
(NASDAQ:DRNA), a leading developer of
investigational ribonucleic acid interference (RNAi) therapeutics, today
announced that Douglas M. Fambrough, Ph.D., president and chief
executive officer, will participate in two investor conferences in

  • H.C. Wainwright 20th Annual Global Investment Conference, Wednesday,
    September 5, 2018 at 1:45 p.m. ET, at The St. Regis in New York. Dr.
    Fambrough will present a corporate update and overview of the
    Company's most advanced GalXC™ pipeline programs, including DCR-PHXC,
    an investigational RNAi therapeutic in development for the treatment
    of all forms of primary hyperoxaluria. A live webcast of the
    presentation can be accessed on the Investors & Media section on the
    Dicerna website at
    An archived replay of the webcast will be available on the Company's
    website after the conference.
  • Citi's 13th Annual Biotech Conference, Thursday, September 6, 2018, in
    Boston. Dr. Fambrough will be available for one-on-one meetings with
    investors at the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative, subcutaneously delivered
RNAi-based therapeutics for the treatment of diseases involving the
liver, including rare diseases, chronic liver diseases, cardiovascular
diseases, and viral infectious diseases. Dicerna is leveraging its
proprietary GalXC™ RNAi technology platform to build a broad pipeline in
these core therapeutic areas, focusing on target genes where connections
between target gene and diseases are well understood and documented.
Dicerna intends to discover, develop and commercialize novel
therapeutics either on its own or in collaboration with pharmaceutical
partners. For more information, please visit

View Comments and Join the Discussion!